Revance Therapeutics Inc (RVNC)

[DewDiligence]

Re: US botulinum-toxin pricing following EOLS’ launch

Most likely, EOLS will settle on a price comparable to Dysport and Xeomin—i.e. a modest discount to Botox. AGN may resort to some short-term direct-to-consumer rebates in aesthetic indications to hinder EOLS’ launch, but AGN won’t cut the list price of Botox or lower the net realized price in therapeutic indications, IMO.

All told, I don’t expect EOLS’ launch to have a material effect on US pricing.